Invivoscribe
Invivoscribe's Overview
Invivoscribe is a global, vertically-integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For nearly thirty years, they have been a leader in developing and commercializing a broad range of IVD products, clinical testing services (through their LabPMM laboratories), and bioinformatics software used in molecular diagnostics and personalized medicine. Their strong focus is on hematologic malignancies and MRD (Minimal Residual Disease) testing, offering solutions from Research Use Only (RUO) to In Vitro Diagnostic (IVD) products, supporting research, clinical trials, and routine clinical testing worldwide.
Where is Invivoscribe's Headquarters?
HQ Function
Serves as the global corporate headquarters, housing key operations including research and development, GMP manufacturing, CLIA/CAP accredited clinical laboratory services (LabPMM San Diego), and global administrative functions.
Notable Features:
State-of-the-art laboratory facilities designed for advanced molecular diagnostics development, manufacturing, and high-complexity clinical testing. Includes capabilities for companion diagnostics development.
Work Culture:
A science-driven, innovative, and collaborative environment focused on quality, precision, and making a tangible impact on patient care. Emphasizes meticulousness due to the nature of diagnostic testing and regulatory compliance.
HQ Significance:
The San Diego headquarters centralizes core strategic, operational, and R&D activities, benefiting from the rich biotech ecosystem, access to a skilled talent pool, and proximity to research institutions and partners.
Values Reflected in HQ: The facility reflects Invivoscribe's commitment to scientific excellence, rigorous quality control (ISO 13485 certified), regulatory compliance, and the advancement of personalized medicine through precision diagnostics.
Location:
Invivoscribe maintains a significant global presence, directly supporting clinical trials, research institutions, and diagnostic laboratories across North America, Europe, and Asia through its strategically located offices and laboratories (LabPMM). The company offers worldwide distribution of its Research Use Only (RUO) and In Vitro Diagnostic (IVD) products, engages in global companion diagnostics development partnerships, and provides internationally accessible clinical laboratory services. Its bioinformatics platforms are also utilized by laboratories globally, underscoring its commitment to improving patient care worldwide.
Street Address:
10222 Barnes Canyon Rd, Bldg 1
City:
San Diego
State/Province:
CA
Country:
USA
Invivoscribe's Global Presence
Martinsried, Germany
Address: Lochhamer Str. 29A, 82152 Martinsried, Germany
Supports European customers, clinical trials, and commercial operations; ensures adherence to European regulatory standards (e.g., IVDR) and provides regional diagnostic services.
Shanghai, China
Address: Room 302, Building 1, No. 18, Ronghua Road East, Shanghai Pilot Free Trade Zone, Shanghai 200131, China
Facilitates market access and growth in China, supports local clinical research collaborations and addresses specific regional healthcare needs.
Tokyo, Japan
Address: Nihonbashi Life Science Building 2, Room 601, 2-3-11 Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023, Japan
Addresses the specific requirements of the Japanese healthcare system and research community, managing local distribution channels and regulatory interactions.
Buying Intent Signals for Invivoscribe
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Invivoscribe
As of April 2025, Invivoscribe' leadership includes:
Investors of Invivoscribe
Invivoscribe has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Invivoscribe has strengthened its executive leadership over the past year, highlighted by the strategic appointment of a new Chief Medical Officer with extensive FDA experience. This move aligns with the company's growth trajectory and focus on clinical and regulatory excellence, particularly following its acquisition by Summa Equity in 2023. No major executive departures have been publicly announced during this period.
New Appointments:
Technology (Tech Stack) used by Invivoscribe
Discover the tools Invivoscribe uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Invivoscribe Email Formats and Examples
Invivoscribe most likely utilizes a standard professional email format, commonly [first_initial][last_name]@invivoscribe.com. This format is prevalent in many companies, particularly in the biotechnology and healthcare sectors, for its simplicity and professionalism.
flast@invivoscribe.com
Format
jmiller@invivoscribe.com
Example
85%
Success rate
News and media
PR Newswire • January 9, 2024
Invivoscribe Appoints Tim Stenzel, M.D., Ph.D. as Chief Medical Officer
Invivoscribe announced the strategic appointment of Tim Stenzel, M.D., Ph.D., as its new Chief Medical Officer. Dr. Stenzel, who previously served as the Director of the Office of In Vitro Diagnostics and Radiological Health (OIR) at the U.S. Food and Drug Administration (FDA), will guide Invivoscribe's clinical development and regulatory affairs....more
Business Wire • April 26, 2023
Summa Equity Acquires Majority Stake in Invivoscribe, a Global Leader in Hematology-Oncology Molecular Diagnostics
Summa Equity, a purpose-driven thematic investment firm, announced its acquisition of a majority stake in Invivoscribe. This partnership aims to accelerate Invivoscribe's mission to expand its global leadership in precision diagnostics for cancer and Minimal Residual Disease (MRD) testing, further enhancing its ability to improve patient outcomes....more
Invivoscribe News • December 7, 2023
Invivoscribe and Beat AML® Present Data Demonstrating Clinical Utility of Assays at ASH 2023
At the 65th American Society of Hematology (ASH) Annual Meeting, Invivoscribe, in collaboration with The Leukemia & Lymphoma Society's Beat AML® Master Clinical Trial, presented significant data. The findings highlighted the clinical utility of Invivoscribe's LymphoTrack®, MyMoid® Track, and MyRaid® Myeloid Assays for comprehensive genomic profiling in acute myeloid leukemia (AML)....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Invivoscribe, are just a search away.